Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate to determine the effect of food on the PK of a single dose of 40 mg Clifutinib in healthy subjects.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Acute Myeloid Leukemia in Children

NCT number NCT05454098
Study type Interventional
Source Sunshine Lake Pharma Co., Ltd.
Contact
Status Completed
Phase Phase 1
Start date November 8, 2022
Completion date December 8, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05792007 - Study of the Medullary Microenvironment in Acute Childhood Leukemia N/A
Recruiting NCT03068819 - Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant Phase 1/Phase 2
Completed NCT03389724 - Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia Phase 3
Not yet recruiting NCT06421155 - Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia N/A
Recruiting NCT05994690 - CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients Phase 3
Recruiting NCT06233526 - Individualized Treatment of Pediatric R/R AML Based on Transcriptomic Profile and in Vitro Drug Sensitivity Test N/A
Recruiting NCT06262438 - CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients Phase 2